本期 13F-HR 中的全部持仓，以及相对上季度的变化。
13F 持仓，最新季度
来源SEC EDGAR13F-HR
GILEAD SCIENCES, INC. (CIK 882095) reported $1.65B across 5 reported positions in its SEC 13F filing for 2026-06-30. Largest positions: RCUS ($968.8M, 58.76%), LKFT ($500.2M, 30.34%), ASMB ($136.8M, 8.30%), KYTX ($36.8M, 2.23%), XLO ($6.2M, 0.38%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | RCUS | Arcus Biosciences Inc. | $968.8M | 58.76% | 31.4M | Hold |
| 2 | LKFT | Lakefront Biotherapeutics | $500.2M | 30.34% | 16.7M | Hold |
| 3 | ASMB | Assembly Biosciences Inc. | $136.8M | 8.30% | 5.0M | Added |
| 4 | KYTX | Kyverna Therapeutics Inc. | $36.8M | 2.23% | 4.1M | Hold |
| 5 | XLO | Xilio Therapeutics Inc. | $6.2M | 0.38% | 650,389 | Hold |
| 6 | ACLX | Arcellx Inc | $0 | 0.00% | 0 | Exited |
来源：SEC 13F 申报文件 · 截至 2026-06-30